Skip to main content
Advertising

Originally published June 19, 2013 at 8:22 AM | Page modified June 19, 2013 at 8:24 AM

  • Share:
             
  • Comments (0)
  • Print

Bluebird Bio shares rocket higher in trading debut

Shares of gene therapy developer Bluebird Bio Inc. are surging in their trading debut.

The Associated Press

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

NEW YORK —

Shares of gene therapy developer Bluebird Bio Inc. are surging in their trading debut.

Its shares climbed $9.15, or 53.8 percent, to $26.15 in morning trading Wednesday after trading as high as $27 earlier in the session.

The company's initial public offering of 5.94 million shares had been priced Tuesday at $17 per share, above its initial expectations of $14 to $16 per share.

That raised $101 million before underwriting costs and other expenses.

Bluebird is developing gene therapies for severe genetic and very rare diseases.

The underwriters of the IPO have the option to buy another 891,000 shares of the Cambridge, Mass., company over the next month.

News where, when and how you want it

Email Icon

The Seattle Times wins top award for multimedia storytelling

The Seattle Times wins top award for multimedia storytelling

Our Sea Change series received a prestigious 2015 DuPont-Columbia award for showcasing the power of storytelling on the Web. Experience the report here.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►